Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
03.09. | Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts | 3 | Seeking Alpha | ||
03.09. | BofA Securities downgrades Erasca stock to Underperform on competitive concerns | 6 | Investing.com | ||
18.08. | Morgan Stanley stuft Erasca-Aktie wegen verzögerter Studiendaten herab | 1 | Investing.com Deutsch | ||
18.08. | Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data | 1 | Investing.com | ||
12.08. | Erasca files $500M mixed securities shelf | 2 | Seeking Alpha | ||
ERASCA Aktie jetzt für 0€ handeln | |||||
12.08. | Erasca, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.08. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08. | Erasca, Inc.: Erasca Reports Second Quarter 2025 Business Updates and Financial Results | 208 | GlobeNewswire (Europe) | Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance... ► Artikel lesen | |
26.06. | Erasca, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
02.06. | Erasca Announces Clearance Of IND Application By FDA For ERAS-4001 | - | RTTNews | ||
02.06. | FDA clears Erasca's new cancer drug applications | 1 | Investing.com | ||
13.05. | Erasca, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
13.05. | Erasca, Inc.: Erasca Reports First Quarter 2025 Business Updates and Financial Results | 127 | GlobeNewswire (Europe) | Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026... ► Artikel lesen | |
13.05. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.05. | Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset | 1 | FierceBiotech | ||
13.05. | FDA clears Erasca's new cancer drug ERAS-0015 | 1 | Investing.com | ||
29.04. | Erasca, Inc.: Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
20.03. | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results | 634 | GlobeNewswire (Europe) | Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well... ► Artikel lesen | |
12.11.24 | Erasca, Inc.: Erasca Reports Third Quarter 2024 Business Updates and Financial Results | 560 | GlobeNewswire (Europe) | Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,33 % | Pfizer prescht nach vorne, BioNTech gerät unter Druck, Eli Lilly feiert eine neue Zulassung und AstraZeneca zieht es nach New York | Wieder einmal überschlagen die Dinge sich in der US-Politik, wobei das Thema Gesundheit eine wichtige Rolle spielt. Reibereien über die staatliche Gesundheitsfürsorge gelten als einer der Hauptgründe... ► Artikel lesen | |
CUREVAC | 4,632 | -0,13 % | CureVac mit SONDERMELDUNG: Könnte die Aktie jetzt komplett drehen - Profis haben bereits gehandelt! | ||
MODERNA | 23,515 | +1,03 % | MODERNA INC zündet Kursrakete - jetzt einsteigen! | ||
PAION | 0,017 | -23,21 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
NOVAVAX | 7,979 | +0,87 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
NANOREPRO | 1,745 | -0,57 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
4SC | 0,858 | -0,92 % | HV-Termine: Hauptversammlungen u.a. bei 4SC, Bastei Lübbe, Janosch, Koch, mVISE, One Touch Football | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 2,020 | -1,94 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
INFLARX | 1,210 | +0,67 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings sichert sich neue Finanzierung und Option auf bis zu 5 Mio. US-Dollar | ||
DEFENCE THERAPEUTICS | 0,502 | +2,03 % | Defence Therapeutics Inc.: Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025 | Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 6,090 | +2,01 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
DYNAVAX | 8,734 | +0,39 % | Dynavax Technologies: Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile | At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited... ► Artikel lesen | |
IBIO | 0,740 | -0,67 % | iBio, Inc.: iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June... ► Artikel lesen |